132297-01-9

Upstream product

• 132260-26-5 1-C-(hydroxymethyl)-6''-deoxy-6''-acetamido-1,3,2',6',3''-pentakis-N-(tert-butoxycarbonyl)kanamycin B 
• 4696-76-8 kananmycin B 
• 132260-23-2 1-C-(hydroxymethyl)-6''-O-<(2,4,6-triisopropylphenyl)sulfonyl>-1,3,2',6',3''-penta-N-BOC-kanamycin B 
• 132260-22-1 C₅₄H₉₁N₅O₂₃S 
• 132260-21-0 C₅₃H₈₉N₅O₂₂S 
• 132260-20-9 C₅₃H₉₁N₅O₂₀S 
• 132260-11-8 1-N-<(benzyloxy)carbonyl>-3,2',6'-tris-N-(tert-butoxycarbonyl)-3''-N-(trifluoroacetyl)kanamycin B 
• 132260-13-0 1-N-<(benzyloxy)carbonyl>-3,2',6',3''-tetrakis-N-(tert-butoxycarbonyl)kanamycin B 
• 132260-12-9 1-N-<(benzyloxy)carbonyl>-3,2',6'-tris-N-(tert-butoxycarbonyl)kanamycin B 
• 132260-10-7 3,2',6'-tris-N-(tert-butoxycarbonyl)-3''-N-(trifluoroacetyl)kanamycin B 
• 132260-09-4 3,2',6'-tris-N-(tert-butoxycarbonyl)kanamycin B 
• 132260-19-6 C₆₁H₉₇N₅O₂₂S 

Relevant academic research and scientific papers

New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6″. Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation

Substitution of the C-1 atom in the 2-deoxystreptamine moiety of gentamicin C2, a broad-spectrum aminoglycoside antibiotic, by an axial hydroxymethyl group has been reported to confer protection against most clinically important bacterial enzym